BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

CENTRALPHL

All Eps Dividend Board Agm Q1 Q2 Q3

CENTRALPHL 28-Feb-2017

(continuation news of CENTRALPHL): and since then the company is not manufacturing any type of Penicillin, Cephalosporin medicine in its factory. Moreover the Company did not take permission from Drug Administrative Authority for production of Steroid and cancer antidote medicine. (cont.2)

CENTRALPHL 28-Feb-2017

In connection with the instruction for closure of production and distribution of Penicillin, Cephalosporin, Steroid, and cancer antidote of 28 medicine companies within next 3 days, the Company informed the following: As necessary set up for manufacturing of Penicillin and Cephalosporin type medicine was not completed, Drugs Administrative Authority suspended the manufacturing of stated medicine (Ref. No. DA/ML-060/05/2341 dated 20.02.2012) (cont.1)

CENTRALPHL 26-Feb-2017

With reference to their earlier news (disseminated by DSE on 22.02.2017) regarding Signing a MOU with Alif Group to sell all 5 existing Directors' shares, the Company has further informed that the MOU between the Company and Alif Group has been signed on February 25, 2017.

CENTRALPHL 22-Feb-2017

The Company has informed that the Board of Directors has decided to sign a MOU with Alif Group that all existing 5 Directors of Central Pharmaceuticals Ltd. will individually and separately sell their respective shares gradually to different Directors/concerns of Alif Group through Block market. After sale of shares by existing Directors of the Company through Block market, the Directors/concerns of Alif Group will form new Board and appoint new Chairman and Managing Director accordingly.

CENTRALPHL 19-Feb-2017

In response to a DSE query dated February 16, 2017, the Company has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike.

CENTRALPHL 25-Jan-2017

(Q2 Un-audited): EPS was Tk. 0.61 for Oct.-December, 2016 as against Tk. 0.28 for Oct.-December, 2015; EPS was Tk. 0.73 for July-December, 2016 as against Tk. 0.55 for July-December, 2015. NOCFPS was Tk. 0.10 for July-December, 2016 as against Tk. 0.07 for July-December, 2015. NAV per share was Tk. 16.46 as of December 31, 2016 and Tk. 15.73 as of June 30, 2016.

CENTRALPHL 22-Jan-2017

The Company has further informed that the meeting under LR 16(1) will now be held on January 25, 2017 at 3:00 PM instead of January 23, 2017 to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2016.

CENTRALPHL 19-Jan-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 23, 2017 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2016.

CENTRALPHL 26-Dec-2016

The Company has informed that it has credited 10% bonus shares for the year ended on June 30, 2016 to the respective shareholders' BO accounts on December 19, 2016.

CENTRALPHL 22-Dec-2016

(Repeat): In response to a DSE query dated December 20, 2016, the Company has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike.

Previous Next page